Vision shapes behavior, and a new study by MIT neuroscientists finds behavior and internal states shape vision. The research, ...

Novartis secures FDA approval for Itvisma, a one-time gene therapy designed to boost motor function across a broad SMA ...

All starting from the same DNA, neurons ultimately take on individual characteristics in the brain and body. Differences in ...

Itvisma contains the active ingredient in Zolgensma approved in 2019 for children younger than 2 years but is reformulated ...

Effective axon regeneration is critical for restoring nerve function in patients with axon injury-related neurological ...

All starting from the same DNA, neurons ultimately take on individual characteristics in the brain and body. Differences in which genes they ...

The authors have performed a potentially valuable new kind of analysis in connectomics, mapping to an interesting developmental problem of synaptic input to sensory neurons. While the analysis itself ...

US FDA approves Novartis’ Itvisma, the only gene replacement therapy for children two years and older, teens, and adults with SMA: Basel Wednesday, November 26, 2025, 09:00 Hrs ...

Although deep learning–based image recognition technology is rapidly advancing, it still remains difficult to clearly explain the criteria AI uses ...

ITVISMA is a prescription gene therapy used to treat adults and children 2 years of age and older with spinal muscular atrophy (SMA). ITVISMA is given as a one-time intrathecal injection. What is the ...

Novartis wins FDA approval for Itvisma, a one-time gene therapy offering broader SMA treatment with sustained motor function ...